AptarGroup, Inc. (Aptar) is a global designer and manufacturer of dispensing, dosing, sealing, and drug delivery solutions used across the pharmaceutical, beauty and personal care, home care, and food and beverage markets. Its portfolio includes pumps, aerosol valves, closures, droppers, spray and nasal systems, inhalation and ophthalmic devices, and active packaging that helps manage moisture and oxygen.
The company integrates polymer and elastomer materials science with precision molding, automation, and device engineering, and provides regulatory and analytical support for healthcare applications. Aptar’s businesses include Aptar Pharma, Aptar Beauty, Aptar Closures, Aptar Digital Health, and Aptar CSP Technologies. Headquartered in Crystal Lake, Illinois, USA, Aptar operates manufacturing and R&D sites worldwide, supplying components and systems that enable safe, reliable product delivery for consumer and healthcare brands.
Also known as AptarGroup, Aptar CSP Technologies, Aptar Digital Health, Aptar Closures, Aptar Beauty + Home, and CSP Technologies.
10 ml refillable travel spray using Nomad Refill tech wins Formes de Luxe Award; custom anodized-aluminum casing with marble cap and patented connector for fast, clean refills.
Partners will create an integrated translational platform to quantify mechanisms, pathways and kinetics of nose-to-brain drug transport using in vitro, in vivo and computational tools.
APF multidose preservative‑free pump line commissioned to serve Latin American markets, cutting lead times and improving local supply agility.
AI analyzes device-generated sounds to verify correct operation and provide objective feedback for training, usability studies and adherence in home self-administration.
USPTO allowed a patent for N‑Sorb, a packaging material that reduces nitrosamines across multiple APIs and may support FDA Orange Book strategies.
Received an ‘A’ on CDP’s Supplier Engagement Assessment for supplier work to cut Scope 3 emissions—especially from purchased raw materials such as plastics.
Published three international patent applications for nasal/pulmonary GLP‑1 formulations (spray‑dried/powder). Preclinical semaglutide PK shows up to 10× Cmax vs oral; ongoing biologics delivery work.
Q1: sales +11% (core flat); net income -8% to $73M; EPS $1.12 (adjusted $1.19, -8% cc); adjusted EBITDA margin 2% vs 20.7%; returned $131M; Gael Touya named CEO effective Sept 1, 2026
